| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 232 0 |
 SM ISO690:2012MAGIS-ESCURRA, Cecile, GUNTHER, Gunar, LANGE, Christoph G., NOI, Autori, CIOBANU, Ana, KRUDU, V.. Treatment outcomes of MDR-TB and HIV co-infection in Europe. In: European Respiratory Journal, 2017, vol. 49, p. 0. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.02363-2016 |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
  European Respiratory Journal |
|
| Volumul 49 / 2017 / ISSN 0903-1936 /ISSNe 1399-3003 | |
|
|
| DOI:https://doi.org/10.1183/13993003.02363-2016 | |
| Pag. 0-0 | |
| Rezumat | |
The ongoing HIV epidemic and the increasing number of patients with drug-resistant tuberculosis (TB) are seriously hampering global TB-control activities, including those in the World Health Organization (WHO) Region Europe. Overall, the prevalence of HIV co-infection in TB patients increased from 3.4% in 2008 to 8% in 2014 in the region [1]. The prevalence of multidrug-resistant (MDR)-TB (drug resistance against at least isoniazid and rifampicin) reported for Europe – 15% in newly diagnosed TB patients and 48% in previously treated TB patients – is the highest in the world [1]. |
|
| Cuvinte-cheie Antitubercular Agents, Coinfection, Communicable Disease Control, data collection, Disease-Free Survival, Europe, Germany, HIV infections, Humans, Kaplan-Meier Estimate, Patient Outcome Assessment, prevalence, Proportional Hazards Models, Regression analysis, Risk, tuberculosis, Multidrug-Resistant |
|
|
|
|
|
